Global phosphoproteome analysis of human bone marrow reveals predictive phosphorylation markers for the treatment of acute myeloid leukemia with quizartinib

  • Treatment with inhibitors of the receptor tyrosine kinase FLT3 are currently studied as promising therapies in acute myeloid leukemia (AML). However, only a subset of patients benefit from these treatments and the presence of activating mutations within FLT3 can predict response to a certain extent only. ...

Download full text files

Export metadata

Metadaten
Author:Christoph Schaab, Felix S. Oppermann, Martin Klammer, Heike Pfeifer, Andreas Tebbe, Thomas OellerichORCiD, Jürgen Krauter, Mark Levis, Alexander E. Perl, Henrik Daub, Björn SteffenGND, Klaus Godl, Hubert ServeORCiDGND
URN:urn:nbn:de:hebis:30:3-335815
DOI:https://doi.org/10.1038/leu.2013.347
ISSN:1476-5551
ISSN:0887-6924
Pubmed Id:https://pubmed.ncbi.nlm.nih.gov/24247654
Parent Title (English):Leukemia
Publisher:Nature Publ. Group
Place of publication:Basingstoke
Document Type:Article
Language:English
Date of Publication (online):2014/05/06
Date of first Publication:2014/01/10
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2014/05/06
Volume:28
Issue:3
Page Number:4
First Page:716
Last Page:719
Note:
Copyright © 2014 Macmillan Publishers Limited This work is licensed under a Creative Commons Attribution 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0/
HeBIS-PPN:364486996
Institutes:Medizin / Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (German):License LogoCreative Commons - Namensnennung 3.0